22 results
424B3
BIAF
BioAffinity Technologies Inc
16 Apr 24
Prospectus supplement
7:19pm
are listed under the symbol “BIAFW.” If we fail to satisfy the continued listing requirements of The Nasdaq Capital Market, such as the corporate governance requirements … in the diagnostics market.
Director Independence
Under the corporate governance standards of Nasdaq, a majority of our directors must meet
POS AM
BIAF
BioAffinity Technologies Inc
1 Apr 24
Prospectus update (post-effective amendment)
8:06pm
to satisfy the continued listing requirements of The Nasdaq Capital Market, such as the corporate governance requirements, the stockholder’s equity … entities and her experience expanding product market share in the diagnostics market.
Director Independence
Under the corporate governance standards
424B5
svbk4ojjd
8 Mar 24
Prospectus supplement for primary offering
12:18pm
424B5
6ozrp29x9p9dh8ok
7 Mar 24
Prospectus supplement for primary offering
9:57pm
424B5
k76b9n mxlzpmjsvqejx
28 Nov 23
Prospectus supplement for primary offering
4:00pm
S-3
2hov 9xqd16xy7vxt
16 Nov 23
Shelf registration
5:23pm
DRS
hdz 6prwt
14 Aug 23
Draft registration statement
12:00am
DEF 14A
5kmawud7
1 May 23
Definitive proxy
2:55pm
PRE 14A
zrs rq6klxl0t50ye
19 Apr 23
Preliminary proxy
9:56pm
10-K
m1gdo0dw06040j956s2w
31 Mar 23
Annual report
3:40pm
424B4
4iv1i1vr
2 Sep 22
Prospectus supplement with pricing info
3:25pm